Martin Fan
Stock Analyst at Wedbush
(2.75)
# 1,959
Out of 4,902 analysts
6
Total ratings
83.33%
Success rate
14.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNAC Cartesian Therapeutics | Initiates: Outperform | $38 | $12.53 | +203.27% | 1 | Jul 9, 2025 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $8 | $1.59 | +403.14% | 1 | May 28, 2025 | |
| ORKA Oruka Therapeutics | Reiterates: Outperform | $40 | $15.36 | +160.42% | 1 | May 15, 2025 | |
| ANAB AnaptysBio | Reiterates: Outperform | $40 | $26.71 | +49.76% | 1 | May 1, 2025 | |
| ARTV Artiva Biotherapeutics | Reiterates: Outperform | $18 | $2.59 | +594.98% | 1 | Mar 25, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $35 | $13.20 | +165.15% | 1 | Mar 20, 2025 |
Cartesian Therapeutics
Jul 9, 2025
Initiates: Outperform
Price Target: $38
Current: $12.53
Upside: +203.27%
Aclaris Therapeutics
May 28, 2025
Initiates: Outperform
Price Target: $8
Current: $1.59
Upside: +403.14%
Oruka Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $40
Current: $15.36
Upside: +160.42%
AnaptysBio
May 1, 2025
Reiterates: Outperform
Price Target: $40
Current: $26.71
Upside: +49.76%
Artiva Biotherapeutics
Mar 25, 2025
Reiterates: Outperform
Price Target: $18
Current: $2.59
Upside: +594.98%
Zenas BioPharma
Mar 20, 2025
Initiates: Outperform
Price Target: $35
Current: $13.20
Upside: +165.15%